49 Wealth Management LLC purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,976 shares of the company's stock, valued at approximately $407,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Continuum Advisory LLC increased its holdings in shares of Kenvue by 2,071.1% in the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares in the last quarter. Clarity Asset Management Inc. purchased a new position in Kenvue during the 4th quarter valued at about $45,000. SBI Securities Co. Ltd. purchased a new position in Kenvue during the 4th quarter valued at about $46,000. Rossby Financial LCC purchased a new position in Kenvue during the 1st quarter valued at about $52,000. Finally, Golden State Wealth Management LLC increased its holdings in Kenvue by 292.0% during the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after acquiring an additional 2,295 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Performance
KVUE stock traded up $0.03 during trading on Wednesday, hitting $20.73. 15,930,192 shares of the company's stock traded hands, compared to its average volume of 16,142,472. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17. The stock has a fifty day moving average price of $22.51 and a two-hundred day moving average price of $22.31. The stock has a market capitalization of $39.77 billion, a price-to-earnings ratio of 37.69, a price-to-earnings-growth ratio of 3.22 and a beta of 0.83.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same quarter last year, the company earned $0.28 EPS. The company's revenue for the quarter was down 3.9% compared to the same quarter last year. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.96%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.
Analyst Upgrades and Downgrades
KVUE has been the subject of a number of recent research reports. Redburn Atlantic initiated coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Evercore ISI began coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. UBS Group raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Finally, Barclays increased their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Monday, May 12th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $25.33.
Read Our Latest Stock Report on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
